Comparative Pharmacology
Head-to-head clinical analysis: BAMATE versus MEPROSPAN.
Head-to-head clinical analysis: BAMATE versus MEPROSPAN.
BAMATE vs MEPROSPAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
The mechanism of action of BAMATE is not well established; it is thought to involve inhibition of monoamine oxidase (MAO) with preferential inhibition of MAO-B at low doses, leading to increased concentrations of dopamine and other biogenic amines in the brain.
Meprobamate is a carbamate derivative that acts as a central nervous system depressant. It potentiates GABA-A receptor activity and inhibits excitatory neurotransmitter release, leading to anxiolytic, sedative, and muscle relaxant effects.
400 mg orally twice daily
Meprobamate: 400-600 mg orally 3-4 times daily, maximum 2400 mg/day.
None Documented
None Documented
Terminal elimination half-life is 2-4 hours in healthy adults. This short half-life necessitates frequent dosing to maintain therapeutic levels.
Clinical Note
moderateFelbamate + Estrone sulfate
"The serum concentration of Estrone sulfate can be decreased when it is combined with Felbamate."
Clinical Note
moderateMeprobamate + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Meprobamate is combined with Fluticasone propionate."
Clinical Note
moderateMeprobamate + Haloperidol
"The risk or severity of adverse effects can be increased when Meprobamate is combined with Haloperidol."
Clinical Note
moderateTerminal elimination half-life: 15 hours. Steady state reached after 3-5 days. No active metabolites.
BAMATE is primarily excreted renally as unchanged drug (approximately 60-70%) and as glucuronide conjugates (20-30%). Fecal elimination accounts for less than 10%.
Renal: 70% as inactive metabolites; fecal: 20% as conjugated metabolites; biliary: 10%.
Category C
Category C
Anxiolytic
Anxiolytic
Felbamate + Cyclosporine
"The metabolism of Cyclosporine can be decreased when combined with Felbamate."